Abstract
Adenosin diphospat (ADP) plays a crucial role in thrombus formation. Therefore its inhibition can control excess platelet generation to prevent cardiovascular events in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). One of ADP’s target receptors, P2Y12 has a limited tissue distribution and is therefore an attractive pharmacological target. Thienopyridines are class of drugs that specifically and irreversibly inhibit the P2Y12 receptor. Three generations exist and in most patients, they are administered in combination with aspirin. Because of possible gastro-intestinal toxicity, a proton pump inhibitor (PPI) is often concomitantly prescribed. However, several studies suspect an interaction between thienopyridines (in particular with clopidogrel) and PPIs which decreases the inhibition of platelet formation and thus enhances the risk for cardiac events. In this review, a concise overview of pharmacokinetic and pharmacodynamic properties of all thienopyridines is given and a critical discussion of the presumed interaction with PPIs is provided.
Keywords: Drug-eluting stent, stent thrombosis, thienopyridines, proton pump inhibitors.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Interaction between Thienopyridines and Proton Pump Inhibitors
Volume: 14 Issue: 3
Author(s): Banu Sahin Yildiz, Mustafa Yildiz and Ibrahim Akin
Affiliation:
Keywords: Drug-eluting stent, stent thrombosis, thienopyridines, proton pump inhibitors.
Abstract: Adenosin diphospat (ADP) plays a crucial role in thrombus formation. Therefore its inhibition can control excess platelet generation to prevent cardiovascular events in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). One of ADP’s target receptors, P2Y12 has a limited tissue distribution and is therefore an attractive pharmacological target. Thienopyridines are class of drugs that specifically and irreversibly inhibit the P2Y12 receptor. Three generations exist and in most patients, they are administered in combination with aspirin. Because of possible gastro-intestinal toxicity, a proton pump inhibitor (PPI) is often concomitantly prescribed. However, several studies suspect an interaction between thienopyridines (in particular with clopidogrel) and PPIs which decreases the inhibition of platelet formation and thus enhances the risk for cardiac events. In this review, a concise overview of pharmacokinetic and pharmacodynamic properties of all thienopyridines is given and a critical discussion of the presumed interaction with PPIs is provided.
Export Options
About this article
Cite this article as:
Yildiz Sahin Banu, Yildiz Mustafa and Akin Ibrahim, Interaction between Thienopyridines and Proton Pump Inhibitors, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140823121002
DOI https://dx.doi.org/10.2174/1871529X14666140823121002 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Mechanisms of Vascular Restenosis: Which Genes are Crucial?
Current Vascular Pharmacology Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Atherosclerosis, Degenerative Aortic Stenosis and Statins
Current Drug Targets Platelets and HIV-1 Infection: Old and New Aspects
Current HIV Research Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design Membrane Ion Channels and Diabetes
Current Pharmaceutical Design Opportunistic Pathogens in Diabetic Foot Lesions
Current Diabetes Reviews Editorial (Thematic Issue: Is Ischemic Stroke an Inflammatory Disease?)
Current Vascular Pharmacology Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hyperglycaemia and Vitamin D: A Systematic Overview
Current Diabetes Reviews Association between Apolipoproteins AI and B and Ultrasound Indicators of Carotid Atherosclerosis
Current Vascular Pharmacology